CAGE Bio, an innovative biotechnology company focused on developing innovative therapies for infection, inflammation and immunology, announced the closing of a $7.2 million over-subscribed Series A financing. The investment was led by professional and angel investor groups consisting of current and former pharmaceutical executives and physicians.

CAGE Bio is a privately-held clinical stage company exploiting its proprietary deep eutectic ionic liquid platform to develop novel products for infection, inflammation and immunology. It is led by a strong team with deep domain expertise and prior track record of successful product development and value creation. For more information visit www.cagebio.com